

The Role of Vaccines In Preventing Antimicrobial Resistance

Dr Rajeka Lazarus

Vaccines Network UK
Severn Pathology Infection Service

News

Vaccines are a critical weapon in the fight against superbugs

Follow

SETH BERKLEY

6 MARCH 2019 • 9:46AM



Save



A nurse takes a patient's temperature during last summer's cholera and typhoid outbreak in Zimbabwe CREDIT: JEKESAI NJIKIZANA/AFP



**THE ALL-PARTY PARLIAMENTARY GROUP
ON VACCINATIONS FOR ALL**

January 2019

Up to £1m funding awarded to develop
bacterial vaccines in global fight against
antimicrobial resistance

[26TH FEBRUARY 2019](#)

[Vaccines for AMR panel discussion event](#)



Vaccines to tackle drug
resistant infections
An evaluation of R&D opportunities



vaccine-injury.info

AN INJURY TO ONE IS AN INJURY TO ALL

No vaccine has ever been tested for carcinogenicity (causing cancer) mutigenicity (damaging DNA) or impairment of fertility (fetal harm).



Brain Damage/Death from Vaccines is NOT Rare



VaxXed Stories: The McDowell Triplets in Michigan (pneumococcal)



Dr James Meehan MD at TxMFA



Fetal Death | Medical Billing Records



Dr Bob Zajac



VaxXed Tour: Brave Dr. Moss in West Virginia



Vaccine Autism Debate - Except When They Do - SafeMinds



Are vaccines to blame for infant deaths?



Dan Burton Questions FDA Rep




Are Vaccinations Safe for Your Kids? CBN report Dr. Blaylock.



Vaccine's Safety: A Crime Against Humanity


javascript:writeEmbedCode("gt3kFxFRo-w","Fetal Death | Medical Billing Records")



Why has antibiotic use and resistance increased despite the use of vaccines?

Reducing Resistance

Graph showing *Haemophilus influenzae* type b laboratory reports by quarter: England, 1990-2014*



*Provisional data

Source: Routine laboratory data combined with reference laboratory data



July 15, 1974

More ▾

Haemophilus influenzae Type B Resistant to Ampicillin

A Report of Two Cases

Waheed Khan, MS; Sydney Ross, MD; William Rodriguez, MD; [et al](#)

JAMA. 1974;229(3):298-301. doi:10.1001/jama.1974.03230410022016





Full
Text

Abstract

Recently, two infants with severe infections due to ampicillin-resistant strains of *Haemophilus influenzae* type B were treated at Children's Hospital National Medical Center. In both cases, it was necessary to change therapy to chloramphenicol. One patient with meningitis died while the second with bacteremia and pneumonia recovered. A survey of 60 recent isolates of *H influenzae* type B in the Washington community showed that 10% were ampicillin-resistant. The enzyme produced by these resistant strains was found to be a β -lactamase. Careful appraisal is now necessary to decide whether ampicillin is the drug of choice as initial therapy in *H influenzae* meningitis in pediatric patients.

(*JAMA* 229:298-301, 1974)



Overall decrease in antibiotic non-susceptible serotypes

Reducing Antibiotic Use

Pneumococcal Conjugate Vaccine

35 antibiotic
prescriptions per 100
vaccinated children
prevented

1.4 million antibiotic
prescriptions
prevented in the US

Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. *Pediatr Infect Dis J* 2003; 22: 10–16

Lee et al Outpatient antibiotic prescribing in the United States: 2000 to 2010 *BMC Medicine* 2014;12:96

Universal Influenza vaccination

64% decrease in antibiotic prescribing for influenza associated infections compared to other provinces

~144 000 antibiotic prescriptions prevented

Universal Influenza vaccination


Reducing secondary
bacterial complications

Reducing inappropriate
prescribing


Havers HP et al. Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons JAMA Netw Open 2018 1;1(2):e180243

Hardelid P et al. Effectiveness of live attenuated influenza vaccine in preventing amoxicillin prescribing in preschool children: a self-controlled case series study Antimicrob Chemother 2018 Mar 1;73(3):779-786.

Norwegian Salmon Farming



NORM NORM 2016



Reduce the Burden of Infection

Reduce the Burden of Infection

Antigen	Optimisation
Pneumococcus	Increase serotype coverage, whole cell vaccine Older adults - improve effectiveness
Influenza	Universal vaccine
Pertussis	Improved duration - recombinant vaccines
Men B	Improve breadth of serotype coverage
HPV	Serotype coverage

Optimise vaccines that
are currently in use

Reduce the Burden of Infection

Group A
Strep

S.aureus

E.coli

Reduce the Burden of Infection

Group A
Strep

S.aureus

E.coli

TB

Malaria

HIV

Reduce the Burden of Resistant Organisms



Gonococcus



CPE



Salmonella

High Risk Populations

High Risk Populations

Children

Elderly

MSM

Transplant

Pregnancy

Surgical

CMV

C.difficile


EBV

MRSA

Transplant

RSV

Candida



Individual Protection

Herd Immunity

High risk groups

Reduce burden of infection

Reduce appropriate and inappropriate antibiotic use

Reduction in AMR

Reduce burden of resistant organisms

Reduce burden of transmissible infection

Multidrug resistant organisms

Hospital acquired infection

Vaccine Uptake



Earliest Year
2013-14


Latest Year
2017-18

Years Shown
5

Region

London


Region coverage (%)



Country


England

Country coverage (%)




● MMR1 at 24m ● MMR1 at 5y ● MMR2 at 5y

Vaccine Hesitancy



Socioeconomic Factors

Influenza vaccine Merseyside



HPV vaccine in South West

Univariable and multivariable model of predictors of initiation of HPV vaccination course

Covariate	N	Unadjusted			Adjusted		
		OR	95% CI	P value	OR	95% CI	P value
Ethnicity							
White British ^a	11 070	1.00	—	—	1.00	—	—
Mixed ethnicity	143	0.78	(0.46–1.32)	0.35	0.94	(0.55–1.61)	0.84
Asian or British Asian	335	0.43	(0.33–0.57)	<0.001	0.59	(0.44–0.80)	0.001
Black or British Black	122	0.33	(0.22–0.51)	<0.001	0.50	(0.32–0.79)	0.003
Chinese and other	179	0.36	(0.25–0.53)	<0.001	0.48	(0.33–0.71)	<0.001
Not stated	2433	0.39	(0.35–0.44)	<0.001	0.44	(0.39–0.50)	<0.001
				<0.001^b		<0.001^b	

Hungerford, D., Ibarz-Pavon, A., Cleary, P., & French, N. (2018). Influenza-associated hospitalisation, vaccine uptake and socioeconomic deprivation in an English city region: an ecological study. *BMJ open*, 8(12), e023275. doi:10.1136/bmjopen-2018-023275

Harriet Fisher, Suzanne Audrey, Julie A. Mytton, Matthew Hickman, Caroline Trotter; Examining inequalities in the uptake of the school-based HPV vaccination programme in England: a retrospective cohort study, *Journal of Public Health*, Volume 36, Issue 1, 1 March 2014, Pages 36–45

Routine Vaccination Practice after Adult and Paediatric Allogeneic and Haematopoietic Stem Cell Transplant

- minority of adult (8%) and paediatric (10%) programmes offer 77 vaccination on site
- Nearly two-thirds (65%) of programmes do not maintain a record of vaccine administration in patients' case notes
- Variation in vaccination time points and vaccinations given

Conclusions

Vaccines prevent AMR by multiple mechanisms. In order to use vaccines to their full potential we need to optimise current use and support vaccine development.

ONLINE COURSE

The Role of Vaccines in Preventing Infectious Diseases and Antimicrobial Resistance


[Go to course](#)[Overview](#)[Topics](#)[Start dates](#)[Requirements](#)[Educators](#)

The UK Clinical Vaccine Network exists to bring updates in vaccinology to clinicians and offer opportunities for clinicians to get involved in vaccine development



[HOME](#) | [FORUM](#) | [RESOURCES](#) |

[CONTACT](#)



Welcome

This online forum is free to join and enables all involved in vaccine development and vaccine use the opportunity to


UK Clinical Vaccine Network Conference 2019

14th June
Oxford

REGISTER NOW

Welcome to the UK Clinical Vaccine Network Conference 2019, a single day conference focusing on the future direction and challenges within the vaccine arena, and set to be the go-to annual conference for all those interested in vaccine development and use. The aim of the conference is to discuss the

Time between deployment of an intervention and the first documented failure in humans due to resistance (marked with “x”s).



David A. Kennedy, and Andrew F. Read PNAS
2018;115:51:12878-12886





Do you need the flu jab?

Asthma?

Heart
disease?

Diabetes?

Weakened
immune system?

Liver
disease?

Lung
disease?


Kidney
disease?



If you have any of these conditions, you are also more likely to develop serious complications from flu, such as pneumonia. Contact your GP today to book your flu jab. It's quick, safe and free.

www.nhs.uk/flu





Andrews NJ et al Impact and Effectiveness of 23-valent Pneumococcal Polysaccharide Vaccine Against Invasive Pneumococcal Disease in the Elderly in England and Wales *Vaccine* 2012 30 (48), 6802-8